Besides the downregulation of ASCL1 itself, that was shown to be essential for the survival of a majority of lung cancers, we discovered that in our experimental conditions, lurbinectedin targets and downregulates 18 genes among the 72 ASCL1‐dependent gene expression signatures previously identified (such as the antiapoptotic regulator BCL2) as neuroendocrine differentiation markers in SCLC (Table EV2) that constitute potential novel druggable targets (Augustyn et al, 2014). The gene discussed is BCL2; the disease is lung carcinoma.